Immunic Inc is a biopharmaceutical company focused on developing innovative treatments for autoimmune and inflammatory diseases
The company is dedicated to advancing therapies that can address unmet medical needs, utilizing a proprietary drug development platform. Immunic is particularly engaged in researching and formulating oral medications that target specific pathways in immune response, with the aim of improving the quality of life for patients suffering from conditions such as multiple sclerosis, ulcerative colitis, and other chronic inflammatory disorders. Through its commitment to scientific excellence and clinical research, Immunic seeks to establish itself as a leader in the field of immunology.
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Immunic, Inc. (NASDAQIMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million.
Immunic Inc (NASDAQIMUX) announced interim data from its phase 2 CALLIPER trial of nuclear receptor-related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), in patients with
